Table 3.

Changes (mean change or change in proportion followed by 95% CI) in medical risk factors and cardioprotective medications in cardiovascular patients between IA, EOP and 6-month assessment

	From IA to EOP					From IA to 6 month follow-up
	n	IA	EOP	Change	P value	n	IA	6 months	Change	P value
Blood pressure (mm Hg)
Systolic blood pressure mean(SD)	62	137.1±15.7	117.6±8.1	−19.5 (−23.2, –15.8)	<0.001	54	137.3±15.9	119.9±11.5	−17.7 (−22.5, –12.5)	<0.001
Diastolic blood pressure mean (SD)	62	75.9±9.3	73.7±8.3	−2.2 (−5.2, 0.9)	0.17	54	75.4±9.0	74.9±7.9	−0.5 (−3.5, 2.5)	0.76
Blood pressure <130/80 (%)	62	24	68	44 (27, 60)	<0.001	54	26	69	43 (25, 59)	<0.001
LDL cholesterol
LDL (mmol/l) mean (SD)	59	2.33±0.88	1.57±0.58	−0.76 (−0.98, –0.54)	<0.001	37	2.18±0.76	1.71±0.74	0.47(−0.77, –0.16)	0.004
LDL <1.4 mmol/L (%)	59	14	41	27 (14, 40)	<0.001	37	14	41	27 (5, 49)	0.02
HbA1c <53* (%)	4	50	50	0 (−25, 25)	1.00	3	67	67	0 (−33, 33)	1.00
Cardioprotective medications
Antiplatelets (%)	64	91	91	0 (−2, 2)	1.00	55	89	89	0 (−2, 2)	1.00
Beta blockers (%)	64	67	66	−1 (−6, 3)	1.00	55	66	62	−4 (−10, 30)	0.50
ACE inhibitors (%)	64	36	36	0 (−9, 9)	1.00	55	35	35	0 (−9, 9)	1.00
ARB’s (%)	64	22	25	3 (−3, 9)	0.5	55	25	31	6 (−2, 13)	0.25
Calcium channel blockers (%)	64	19	22	3 (−3, 9)	0.5	55	18	24	6 (−2, 2)	0.25
Statins (%)	64	84	88	2 (−5, 11)	0.63	55	82	82	0 (−11, 11)	1.00
Other lipid lowering medications (%)	64	5	17	12 (3, 22)	0.008	55	5	22	17 (5, 28)	0.004

*In those with known diabetes.

ARBs, angiotensin II receptor blockers; EOP, end of programme; HbA1c, glycosylated haemoglobin; IA, initial assessment; LDL, low-density lipoprotein.